Compare XBIT & INFU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIT | INFU |
|---|---|---|
| Founded | 2005 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Pharmaceuticals and Biotechnology | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 74.4M | 208.8M |
| IPO Year | 2015 | 2005 |
| Metric | XBIT | INFU |
|---|---|---|
| Price | $2.37 | $9.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $15.00 |
| AVG Volume (30 Days) | 27.1K | ★ 256.6K |
| Earning Date | 05-08-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 181.82 |
| EPS | N/A | ★ 0.05 |
| Revenue | N/A | ★ $143,436,000.00 |
| Revenue This Year | N/A | $3.20 |
| Revenue Next Year | N/A | $7.31 |
| P/E Ratio | ★ N/A | $182.40 |
| Revenue Growth | N/A | ★ 6.36 |
| 52 Week Low | $2.09 | $5.43 |
| 52 Week High | $3.61 | $11.04 |
| Indicator | XBIT | INFU |
|---|---|---|
| Relative Strength Index (RSI) | 39.06 | 49.32 |
| Support Level | $2.26 | $8.57 |
| Resistance Level | $2.69 | $9.97 |
| Average True Range (ATR) | 0.07 | 0.51 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 10.34 | 38.85 |
XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.
InfuSystems Holdings Inc is a health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers. The company's services are provided under two-reportable segments: Patient Services and Device Solutions. Maximum revenue is generated from its Patient Services segment, which provides Durable Medical Equipment (DME) and treatment consumables, handles order and delivery logistics, provides 24/7 nursing support relating to the provided equipment, assumes responsibility for third-party payer Durable Medical Equipment billing, and handles biomedical services for the Durable Medical Equipment. The Device Solutions segment includes equipment rental and sales, consumable sales, and biomedical support services.